Sempra enters September with the Street cutting price targets across the board, options hedging at its highest level in months, and the stock trying to claw back a difficult August from $84.26.
The analyst activity this week tells the clearest story. Target cuts have come from every direction — JP Morgan's Aidan Kelly trimmed his target to $102 from $113 on September 2 while staying Overweight, and Jefferies upgraded the rating to Buy but still cut its target to $97 from $101, a mixed signal if ever there was one. The most bearish move came from Mizuho, which on August 31 downgraded from Outperform to Neutral and slashed its target from $104 to $84 — essentially street level with where the stock closed. Morgan Stanley and Truist had already moved lower in the weeks prior. The consensus mean target is $102, implying about 21% upside from current levels, but the trajectory of those targets is uniformly downward. Analysts are not abandoning the name — the majority maintain constructive ratings — but they are resetting expectations.
Options positioning confirms that broader caution. The put/call ratio has climbed to 0.70, running nearly 1.5 standard deviations above its 20-day average of 0.48. That is close to the most defensive posture in the options market seen on this stock over the past year, with only the 52-week high of 1.07 sitting above it. Looking at the history, the PCR spent most of July and early August below 0.35 — then pivoted sharply higher from around August 17 onwards, tracking the Mizuho downgrade and the broader wave of target cuts almost tick-for-tick. Short interest, by contrast, tells a less charged story: at 1.67% of the free float, it is low by any measure and has been falling — down 7% on the week and nearly 18% over the past month. Borrow is essentially free at 0.36%, and availability is extraordinarily loose, running at or above the 9,999% ceiling that flags maximum supply. There is no short-side pressure building here; the caution is expressed in options, not in the lending market.
The bull and bear cases on SRE are well-defined. Bulls point to Sempra's regulated utility base, its 80% ownership of Oncor in Texas, and an infrastructure pipeline that should generate durable earnings growth through the decade — a case supported by a forward earnings growth factor ranking in the 83rd percentile. The dividend score ranks in the 96th percentile, reflecting the income credentials that attract the institutional ownership base: BlackRock, Vanguard, and Wellington together hold more than 23% of shares, and recent institutional flow has been broadly additive. Bears focus on declining net income at Sempra Infrastructure, exposure to wildfire liability risk in California, and LNG project execution risk. The valuation does not offer obvious shelter: the stock trades at roughly 15.7x earnings and 15x EV/EBITDA, multiples that have compressed modestly over 30 days but remain stretched relative to a stock that has now lost nearly 5% on the month. The ORTEX short score sits at 31.4 — low, placing it in the 61st percentile — consistent with a name where conviction on the short side is limited.
The stock's most recent earnings reaction is worth noting as context. When Sempra reported on August 6, the shares dipped 0.9% on the day but recovered 2.1% over the following five trading sessions — suggesting that the post-earnings drift tends to be supportive even when the immediate read is negative. The next earnings event is not until November 4, leaving a two-month window in which the analyst target reset, rather than a fundamental catalyst, is likely to dominate sentiment. Peers provided little directional cover this week: WEC and AEE both dipped modestly, CNP added 1.4%, and CMS slid 1.1% — a flat-to-mixed read across the regulated utility space that offers Sempra no particular tailwind.
The next thing to watch is whether the Mizuho downgrade's target of $84 — essentially the current price — acts as a gravitational anchor or whether bulls use the analyst reset as an entry point ahead of the November earnings print.
See the live data behind this article on ORTEX.
Open SRE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
